ES2587591T3 - Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino - Google Patents

Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino Download PDF

Info

Publication number
ES2587591T3
ES2587591T3 ES14188791.9T ES14188791T ES2587591T3 ES 2587591 T3 ES2587591 T3 ES 2587591T3 ES 14188791 T ES14188791 T ES 14188791T ES 2587591 T3 ES2587591 T3 ES 2587591T3
Authority
ES
Spain
Prior art keywords
breast cancer
cancer recurrence
patient
endocrine treatment
predicting breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14188791.9T
Other languages
English (en)
Inventor
Christoph Petry
Inke Sabine Feder
Mathias Gehrmann
Guido Henning
Karsten Weber
Christian VON TÖRNE
Ralf Kronenwett
Mareike Dartmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sividon Diagnostics GmbH
Original Assignee
Sividon Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sividon Diagnostics GmbH filed Critical Sividon Diagnostics GmbH
Application granted granted Critical
Publication of ES2587591T3 publication Critical patent/ES2587591T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un método para predecir el resultado del cáncer de mama en un tumor positivo para receptores de estrógeno y negativo para HER2 de un paciente con cáncer de mama, comprendiendo dicho método: (a) determinar en una muestra tumoral de dicho paciente los niveles de expresión de ARN de los siguientes 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, y MGP (b) combinar matemáticamente los valores de los niveles de expresión para los genes de dicho conjunto cuyos valores se determinaron en la muestra tumoral para proporcionar una puntuación combinada, en donde dicha puntuación combinada es indicativa de una prognosis de dicho paciente.
ES14188791.9T 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino Active ES2587591T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158561 2010-03-31
EP10158561 2010-03-31

Publications (1)

Publication Number Publication Date
ES2587591T3 true ES2587591T3 (es) 2016-10-25

Family

ID=43857901

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14188791.9T Active ES2587591T3 (es) 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
ES11710526.2T Active ES2525382T3 (es) 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11710526.2T Active ES2525382T3 (es) 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino

Country Status (16)

Country Link
US (5) US20130065786A1 (es)
EP (2) EP2845911B1 (es)
JP (2) JP5940517B2 (es)
KR (1) KR101864855B1 (es)
CN (2) CN102971435B (es)
BR (2) BR122020016370B1 (es)
CA (1) CA2793133C (es)
ES (2) ES2587591T3 (es)
HU (1) HUE030164T2 (es)
MX (1) MX2012011167A (es)
PL (2) PL2845911T3 (es)
PT (2) PT2845911T (es)
RU (1) RU2654587C2 (es)
UA (1) UA110790C2 (es)
WO (1) WO2011120984A1 (es)
ZA (1) ZA201207229B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP2845911B1 (en) 2010-03-31 2016-05-18 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
HUE032391T2 (en) 2011-07-28 2017-09-28 Sividon Diagnostics Gmbh Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer
SG10202010758SA (en) * 2011-11-08 2020-11-27 Genomic Health Inc Method of predicting breast cancer prognosis
CA2874492C (en) * 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
US9890430B2 (en) 2012-06-12 2018-02-13 Washington University Copy number aberration driven endocrine response gene signature
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
US20150376714A1 (en) 2013-02-01 2015-12-31 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
KR20160005731A (ko) * 2013-05-07 2016-01-15 국립연구개발법인 고쿠리츠간켄큐센터 위암의 재발을 예측하는 방법
JP2016519935A (ja) * 2013-05-13 2016-07-11 ナノストリング テクノロジーズ，インコーポレイティド 結節陽性の初期乳癌における再発リスクを予測する方法
WO2015015000A1 (en) * 2013-08-02 2015-02-05 Université Catholique de Louvain Signature of cycling hypoxia and use thereof for the prognosis of cancer
BR112016005225B1 (pt) * 2013-09-11 2023-11-14 Bio Theranostics, Inc Métodos para avaliar câncer de mama em um indivíduo
EP3049536B1 (en) * 2013-09-23 2019-05-22 The University of Chicago Methods and compositions relating to cancer therapy with dna damaging agents
KR101548830B1 (ko) * 2013-12-30 2015-08-31 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물
JP6700186B2 (ja) * 2014-01-22 2020-05-27 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 療法の適合性を評価するための改善された患者の層別化
RU2566732C1 (ru) * 2014-07-08 2015-10-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) Способ прогнозирования лимфогенного метастазирования при инвазивной карциноме неспецифического типа молочной железы
CN104263815B (zh) * 2014-08-25 2017-01-25 复旦大学附属肿瘤医院 一组用于激素受体阳性乳腺癌预后的基因及其应用
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
EP3274476B1 (en) 2015-03-25 2023-06-07 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
CA3016677A1 (en) * 2016-03-09 2017-09-14 Myriad International Gmbh Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy
CN109069602B (zh) * 2016-04-14 2022-11-22 刘扶东 抑制scube2，一种新颖vegfr2辅助受体，抑制肿瘤血管发生
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
CN106480201A (zh) * 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒
EP3985127A1 (en) * 2016-10-27 2022-04-20 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
KR101896545B1 (ko) * 2016-11-25 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
RU2671557C1 (ru) * 2017-07-10 2018-11-02 Александр Григорьевич Тоневицкий Набор реагентов для определения риска возникновения рецидива онкологических заболеваний молочной железы
CA3075265A1 (en) * 2017-09-08 2019-03-14 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
IL276089B2 (en) * 2018-01-22 2024-07-01 Liquid Biopsy Res Llc Methods for colon cancer detection and treatment monitoring
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
CN108715804A (zh) * 2018-05-14 2018-10-30 浙江大学 一种群智能寻优的肺癌癌细胞检测仪
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
WO2020118245A1 (en) * 2018-12-06 2020-06-11 Georgia State University Research Foundation, Inc. Quantitative centrosomal amplification score to predict local recurrence of ductal carcinoma in situ
JP7762135B2 (ja) * 2019-07-05 2025-10-29 インテレクソン・ゲーエムベーハー 個人のｈｌａパターンの決定、予後因子としての使用、標的遺伝子、及び治療薬
CN114830258A (zh) * 2019-09-16 2022-07-29 斯坦福大学托管董事会 基于乳腺癌的分子表征的治疗方法
KR102325945B1 (ko) * 2020-04-22 2021-11-12 아주대학교산학협력단 두경부암 예후 예측용 바이오마커 조성물
EP3907301A1 (en) * 2020-05-08 2021-11-10 Istituto Europeo di Oncologia S.r.l. Methods and kits for determining the risk of breast cancer recurrence
CN112852968A (zh) * 2021-04-08 2021-05-28 杨文琳 基于免疫相关lncRNA构建三阴性乳腺癌风险预测方法
CN114480652A (zh) * 2022-02-21 2022-05-13 深圳市陆为生物技术有限公司 评价乳腺癌患者对于辅助内分泌治疗的响应性的产品
CN115998886B (zh) * 2022-08-22 2026-04-07 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Trim29在乳腺癌免疫治疗中应用
WO2026008886A1 (en) * 2024-07-05 2026-01-08 Immatics Biotechnologies Gmbh Means and methods for the quantification of target expression

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
JP4277452B2 (ja) 2000-02-25 2009-06-10 ソニー株式会社 記録装置、再生装置
EA006512B1 (ru) * 2001-04-27 2005-12-29 Институт молекулярной биологии им. В.А.Энгельгардта РАН Способы анализа последовательностей нуклеиновых кислот с использованием биологического олигонуклеотидного микрочипа и наборы для их осуществления
AU2002346008A1 (en) 2001-06-28 2003-03-03 Dermtech International Method for detection of melanoma
US20040002067A1 (en) 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
ES2504242T3 (es) * 2004-02-20 2014-10-08 Janssen Diagnostics, Llc Pronóstico de cáncer de mama
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
JP4939425B2 (ja) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
EP1848825A2 (en) 2005-02-04 2007-10-31 Rosetta Inpharmatics LLC. Methods of predicting chemotherapy responsiveness in breast cancer patients
CN101356532B (zh) * 2005-05-13 2012-08-01 布鲁塞尔自由大学 基于基因的算法型癌症预后
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0512299D0 (en) 2005-06-16 2005-07-27 Bayer Healthcare Ag Diagnosis prognosis and prediction of recurrence of breast cancer
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
WO2008006517A2 (en) * 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
EP2061885A4 (en) * 2006-09-15 2011-03-09 Univ Mcgill STROMA-DERIVED PREDICTOR FOR BREAST CANCER
CA2671461C (en) 2006-12-01 2014-01-28 The Regents Of The University Of California Vesicles of self-assembling block copolymers and methods for making and using the same
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
EP2036988A1 (en) 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009095319A1 (en) 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
ES2457534T3 (es) * 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
EP2469440A3 (en) 2008-06-16 2014-01-01 Sividon Diagnostics GmbH Molecular markers for cancer prognosis
WO2010003773A1 (en) * 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
EP2163649A1 (en) * 2008-09-11 2010-03-17 Fédération Nationale des Centres de Lutte Contre le Cancer Molecular classifier for evaluating the risk of metastasic relapse in breast cancer
KR101161789B1 (ko) 2008-12-10 2012-07-03 한국생명공학연구원 간암에 대한 신규 바이오마커 및 그의 용도
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
EP2419532A1 (en) 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
JP2012527631A (ja) 2009-05-22 2012-11-08 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ タキサン型化学療法剤用のインジケータとしてのｓｅｒ４７３でのａｋｔリン酸化反応
WO2011121028A1 (en) 2010-03-30 2011-10-06 Siemens Healthcare Diagnostics Inc. Algorithm for prediction of benefit from addition of taxane to standard chemotherapy in patients with breast cancer
EP2845911B1 (en) 2010-03-31 2016-05-18 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
EP2705370A2 (en) 2011-05-06 2014-03-12 Xentech Markers for cancer prognosis and therapy and methods of use
HUE032391T2 (en) 2011-07-28 2017-09-28 Sividon Diagnostics Gmbh Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer
WO2013078537A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
US9890430B2 (en) 2012-06-12 2018-02-13 Washington University Copy number aberration driven endocrine response gene signature
EP3105344A1 (en) 2014-02-12 2016-12-21 Myriad Genetics, Inc. Method for predicting the response and survival from chemotherapy in patients with breast cancer
CN106480201A (zh) 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒

Also Published As

Publication number Publication date
EP2553118A1 (en) 2013-02-06
CN105821125A (zh) 2016-08-03
EP2845911A1 (en) 2015-03-11
CN102971435A (zh) 2013-03-13
EP2553118B1 (en) 2014-10-15
US20240229150A1 (en) 2024-07-11
PL2553118T3 (pl) 2015-03-31
RU2012146343A (ru) 2014-05-10
KR20130010048A (ko) 2013-01-24
CN102971435B (zh) 2016-05-11
UA110790C2 (uk) 2016-02-25
US10577661B2 (en) 2020-03-03
AU2011234573B2 (en) 2015-10-01
AU2011234573A1 (en) 2012-09-20
PT2845911T (pt) 2016-08-25
MX2012011167A (es) 2013-02-07
HK1181817A1 (en) 2013-11-15
CA2793133A1 (en) 2011-10-06
US11913078B2 (en) 2024-02-27
US20130065786A1 (en) 2013-03-14
US20210123107A1 (en) 2021-04-29
US20170067118A1 (en) 2017-03-09
WO2011120984A1 (en) 2011-10-06
HUE030164T2 (en) 2017-05-29
US10851427B2 (en) 2020-12-01
JP5940517B2 (ja) 2016-06-29
RU2654587C2 (ru) 2018-05-21
BR112012024718A2 (pt) 2017-01-10
JP2016189781A (ja) 2016-11-10
US20200224281A1 (en) 2020-07-16
PT2553118E (pt) 2014-12-17
ES2525382T3 (es) 2014-12-23
PL2845911T3 (pl) 2017-01-31
ZA201207229B (en) 2013-06-26
KR101864855B1 (ko) 2018-07-13
EP2845911B1 (en) 2016-05-18
JP2013523105A (ja) 2013-06-17
CA2793133C (en) 2019-08-20
BR122020016370B1 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
ES2587591T3 (es) Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Wang et al. Clinicopathologic significance of miR-10b expression in gastric carcinoma
Li et al. MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
Yu et al. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
ES2721639T3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
Inns et al. Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease
JP2014532428A5 (es)
WO2011122857A3 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
Wu et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node
Chen et al. Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis
ES2548299A1 (es) Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama
Mao et al. MicroRNA‐222 expression and its prognostic potential in non‐small cell lung cancer
Zhuang et al. Downregulation of miR-361-5p associates with aggressive clinicopathological features and unfavorable prognosis in non-small cell lung cancer
MXPA06014175A (es) Diagnostico o pronostico del curso del cancer de mama.
Na et al. Ovarian cancer: markers of response
Zhang et al. Clinicopathological and prognostic significance of miR-4317 expression in gastric cancer patients.
Lijing et al. Differential expressions of microRNAs in rectal adenocarcinoma tissues
Moazeni-Roodi et al. Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
Tang et al. Decreased miR-452 expression in human colorectal cancer and its tumor suppressive function
Ng et al. Non-invasive microrna signatures from the plasma of breast cancer patients reveals sensitive and specific marker for breast cancer screening
Bouchardy Reply: Axillary Lymph Node Ratio Revisited
Vergho et al. 314 MiR200c as outcome predictor of renal cell cancer patients with tumor thrombus of the inferior vena cava (IVC)